FINWIRES · TerminalLIVE
FINWIRES

Visa在第二季度业绩超预期后,上调了2026财年增长预期。

By

-- Visa (V) 股价周三早盘上涨,此前这家支付巨头上调了全年增长预期,并公布了好于预期的第二财季业绩。 该公司在周二晚间发布的财报中表示,目前预计2026财年调整后每股收益将增长两位数左右,调整后营收将增长两位数左右至两位数(均以固定汇率计算)。此前,该公司预计这两项指标将分别增长两位数左右。 FactSet 目前对 Visa 2026财年非GAAP每股收益的普遍预期为12.98美元,营收为450.5亿美元。该股在最近的盘前交易中上涨了4.5%。 据FactSet发布的财报电话会议记录显示,首席财务官克里斯托弗·苏在财报电话会议上表示,上调营收增长预期反映了公司“年初至今的强劲业绩”以及目前对“驱动因素、激励措施、波动性和预期更高的增值服务收入增长”的假设,其中也包含了客户对即将到来的FIFA世界杯日益高涨的热情。 苏表示,尽管中东冲突在短期内带来了不确定性,尤其是在中东欧、中东和非洲地区的跨境旅行支出方面,但Visa仍然预期宏观层面的消费者支出将保持稳定。 苏告诉分析师,公司预测,由于2026年FIFA世界杯,美国和拉丁美洲的入境旅游将有所改善。 截至3月底的三个月期间,调整后每股收益从去年同期的2.76美元增至3.31美元,高于华尔街预期的3.10美元。营收增长17%至112.3亿美元,超过分析师平均预期的107.5亿美元。按固定汇率计算,营收同比增长16%。 首席执行官瑞安·麦克纳尼在一份声明中表示:“消费者支出保持韧性,我们的战略和创新推动了消费者支付、商业和资金流动解决方案以及增值服务的强劲表现。” Visa跨境交易量(不包括欧洲境内的交易)按固定汇率计算增长11%。据徐先生透露,支付量按固定汇率计算同比增长9%,其中美国市场增长8%。徐先生在电话会议上表示,国际市场的支付量增长了10%。 服务收入增长13%至49.8亿美元,数据处理收入增长18%至55.4亿美元。国际交易收入增长10%至36.3亿美元。苏告诉分析师,其他收入飙升41%,主要得益于咨询和其他增值服务(尤其是营销服务收入)的增长以及定价策略的调整。 Visa预计,在接下来的三个月中,按固定汇率计算,调整后每股收益和净收入将分别实现中高个位数和低两位数的增长。华尔街预期其非GAAP每股收益为3.20美元,销售额为112.4亿美元。

Related Articles

Australia

Ryde Signs MoU With VinaTaxi to Explore Vietnam Opportunities

Ryde Group (RYDE) said Wednesday that it has signed a memorandum of understanding with VinaTaxi to explore strategic collaboration opportunities in Vietnam.The areas of exploration include the deployment of Ryde's platform within VinaTaxi's taxi fleet, and the development of an electric motorcycle ride-hailing ecosystem, the company said.Price: $1.20, Change: $+0.02, Percent Change: +1.61%

$RYDE
Research

Research Alert: Biogen Q1 Earnings: Strong Beat Overshadowed By Lowered Full-year Eps Guidance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Biogen delivered strong Q1 2026 results with non-GAAP EPS of $3.57 (+18% Y/Y) significantly exceeding the consensus of $2.95, while revenue of $2.478B (+2% Y/Y) beat expectations of $2.2B. Growth products sustained impressive momentum, generating $851M (+12% Y/Y), now representing one-third of total revenue, with LEQEMBI collaboration revenue up 80% Y/Y to $60M and the MS franchise showing better-than-expected resilience at $779M (-4% Y/Y). We view the continued acceleration of growth products as demonstrating successful portfolio diversification away from MS dependence. Management downgraded 2026 non-GAAP EPS guidance to $14.25-$15.25 from $15.25-$16.25, primarily reflecting acquired IPR&D charges. The proposed $5.6B Apellis acquisition, expected to close in Q2 2026, will add SYFOVRE and EMPAVELI to the growth portfolio and is anticipated to be accretive in 2027, in our view. We expect the combined revenue from these assets to grow in the mid-to-high teens for at least the next two years.

$BIIB
Australia

Emergent BioSolutions Signs $50 Million Contract to Support SAB Biotherapeutics' Lead Program

Emergent BioSolutions (EBS) said Wednesday it has signed a $50 million multi-year agreement with SAB Biotherapeutics (SABS) to help advance SAB-142 lead program in clinical development for autoimmune type 1 diabetes.Under the agreement, $36 million is contingent on future regulatory approval and downstream milestones, according to a statement.Emergent BioSolutions will provide end-to-end development and manufacturing services that are compliant with current good manufacturing practices, the company said.Price: $8.17, Change: $-0.07, Percent Change: -0.79%

$EBS$SABS